Rst-001 (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
90 | Retinitis pigmentosa | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02556736 (ClinicalTrials.gov) | December 14, 2015 | 21/9/2015 | RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa | Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP) | Advanced Retinitis Pigmentosa | Drug: RST-001 | Allergan | NULL | Active, not recruiting | 18 Years | N/A | All | 14 | Phase 1;Phase 2 | United States |